COMPANY PROFILE

Avisi Technologies

Explore full profile

Develops a nanotechnology-enabled defense against blindness from glaucoma

Redwood City, United StatesFounded 2017Health Tech & Medtech

Valuation $50–100M Last recorded · 2026

Headcount <100 Current team size

Total funding $10–50M Disclosed equity funding

Unlock exact values

About Avisi Technologies

Avisi Technologies is a pioneering MedTech company focused on developing innovative solutions for ophthalmic conditions. The company's flagship product, VisiPlate, is an investigational aqueous shunt designed to lower intraocular pressure in patients with open-angle glaucoma. VisiPlate is notable for its ultrathin design, which is several times thinner than a human hair, aiming to provide greater patient comfort and improved aesthetics. Avisi Technologies operates in the medical technology market, primarily serving ophthalmologists and patients suffering from glaucoma. The business model revolves around the development, clinical testing, and eventual commercialization of advanced medical devices. Revenue generation is expected to come from the sale of these devices once they receive regulatory approval. The company has generated significant interest through promising clinical trial results and presentations at major medical conferences.

MoreLess Source: Dealroom company data

At a glance

Status: Operational
Founded: 2017
Headquarters: Redwood City, United States
Employees: 18
Open positions: None listed
Dealroom signal: 72.9/100
Industry: Health
Sub-industry: Medical Devices
Sector: Health Tech & Medtech, Ophthalmology, medical implants, Spinout, DT and LS, science-based
Technology: Deep Tech, Nanotech
Business model: Manufacturing
Client focus: b2b
Links: Website LinkedIn X

Knowledge graph

Founder mafia, market maps, research and news connected to this company by Dealroom

Funding history

10 recorded events

Company financing events and reported valuations.

Deal type	Date	Amount	Valuation	Investors	Source
SERIES AOther financing	Feb 2026	$11M	$43M	Golden Seeds · Good Growth Capital · Gemseki · Quaker Capital Investments	↗
SEEDOther financing	Oct 2023	$2.3M	$9.2M	MedVenture Partners	—

Showing the latest 2 of 10 recorded eventsBook a demo for the full funding history →

Growth signals

Avisi Technologies website traffic

Latest recorded traffic for Avisi Technologies is 2.9K monthly website visits, down 6.5% over the last three months. Avisi Technologies's team declined 14.3% over the past year.

Latest monthly visits2.9K 3-month web change-6.5% 1-year team growth-14.3%

Monthly website visitsOct 2020–Jul 2026

Explore monthly traffic historyTrack growth over time and compare with peersBook a demo

Summary metrics are public; monthly history is available with a demoCompare with peers →

Similar companies

Closest operating peers by Dealroom taxonomy

Company identity and context are open; selected comparison metrics preview what is available on the platform.

Company	Headquarters	Status	Employees	Total funding	Valuation
VIVIVOLTAGuiding the body to heal itself	Waalre, Netherlands	Operational	37	$9.3M	$31M
EPEyed PharmaSustained-release micro-implants for ophthalmic diseases	Liège, Belgium	Operational
EMEyeYon MedicalDevelops and brings to market exclusive medical ophthalmic devices, which offer relief to the unmet clinical needs of millions of patients	Jerusalem, Israel	Operational
SVSamsara VisionSamsara Vision’s next-generation ophthalmic treatments improve sight and everyday life for people with severe vision disorders	Far Hills, United States	Operational
INInjectpowerUltra-miniature batteries enable the development of smart implantable devices with autonomous power	Moirans, France	Operational
PVPixium VisionDevelops retinal implant systems for patients who have lost their eyesight	Paris, France	Operational
IPINEYE PHARMASustained-release ocular insert for chronic eye diseases.	Coimbra, Portugal	Operational
ININBRAIN NeuroelectronicsHigh-resolution graphene interfaces for precision neurology.	Barcelona, Spain	Operational